Investor's Business Daily on MSN4mon
Merck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping PunchMerck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback